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The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development
and metastatic spread of several tumor types including breast, ovarian and gastric
cancer. In breast cancer, HER-2/neu is expressed in early disease development in a
large percentage of DCIS lesions and its expression is associated with an increased
risk of invasion and recurrence. Targeting HER-2 with antibodies such as trastuzumab
or pertuzumab has improved survival, but patients with more extensive disease may
develop resistance to therapy. Interestingly, response to HER-2 targeted therapies
correlates with presence of immune response genes in the breast. Th1 cell production of
the cytokines interferon gamma (IFNγ) and TNFα can enhance MHC class I expression,
PD-L1 expression, augment apoptosis and tumor senescence, and enhances growth
inhibition of many anti-breast cancer agents, including anti-estrogens and HER-2
targeted therapies. Recently, we have identified that a loss of anti-HER-2 CD4 Th1 in
peripheral blood occurs during breast tumorigenesis and is dramatically diminished, even
in Stage I breast cancers. The loss of anti-HER-2 Th1 response is specific and not
readily reversed by standard therapies. In fact, this loss of anti-HER-2 Th1 response in
peripheral blood correlates with lack of complete response to neoadjuvant therapy and
diminished disease-free survival. This defect can be restored with HER-2 vaccinations
in both DCIS and IBC. Correcting the anti-HER-2 Th1 response may have significant
impact in improving response to HER-2 targeted therapies. Development of immune
monitoring systems for anti-HER-2 Th1 to identify patients at risk for recurrence could
be critical to improving outcomes, since the anti-HER-2 Th1 response can be restored
by vaccination. Correction of the cellular immune response against HER-2 may prevent
recurrence in high-risk patients with DCIS and IBC at risk of developing new or recurrent
breast cancer.
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INTRODUCTION
Cancer immunotherapy has garnered considerable interest,
especially in the treatment of HER2/neu positive breast cancer.
HER2/neu (ErbB2) is a protooncogene identified in breast,
ovarian, gastric and bladder carcinoma (Ménard et al., 2001).
Overexpression of the HER2/neu oncodriver typically confers a
more aggressive phenotype with a poorer prognosis, especially in
breast cancer (BC). Present in approximately 20–25% of invasive
breast cancers (IBC) (Meric et al., 2002), overexpression of the
HER2 receptor tyrosine kinase is associated with more advanced
stage disease at presentation and a rapidly progressive clinical
course, including enhanced local-regional extent, early metastatic
spread, and resistance to chemotherapy (Pohlmann et al., 2009),
all of which contribute to poor clinical outcomes. In cases of
in situ disease, HER2 overexpression is a powerful predictor of
presence of invasion, so in situ disease with HER2 positive status
is more likely to harbor invasive foci than HER2 negative lesions
(Roses et al., 2009).
Understanding the biology of the HER2 oncogene is
fundamental to devising and maximizing clinical treatment of
the associated BC. HER2 is a type 1 transmembrane protein
receptor tyrosine kinase, and when it is overexpressed, it is able
to interact with any available receptor tyrosine kinase binding
partner, even in the absence of ligand (Elster et al., 2015). This
leads to a cascade of downstream signaling in pathways, such
as the phosphoinositide-3-kinase pathway, which promote cell
growth, proliferation, and metastasis (Subbiah and Gonzalez-
Angulo, 2014). Blocking the progression of any these pathways
will lead to suppression of HER2 positive disease.
Treatment of HER2/neu positive breast cancer has been
dramatically improved with specific immunotherapy with
monoclonal antibodies including trastuzumab and pertuzumab
(O’Sullivan and Smith, 2014; Zanardi et al., 2015). Despite the
groundbreaking success of monoclonal antibody treatments, a
significant portion of patients develop recurrence after treatment.
There is growing evidence that anti-HER2 CD4+ T helper cell
(Th1) immunity plays a crucial role in cancer therapy and
weak Th1 responses are suggestive of poor treatment response
and prognosis (Datta et al., 2016). This role for Th1 immunity
is likely due to the fact that CD4+ T helper cells mediate
multiple components of both the innate and adaptive immune
system response to tumors. Some mechanisms of potential
Th1 cell activity include direct cytotoxic tumoricidal activity,
modification of antitumor cytokine responses and potentiation
of long term immunologic memory (Cintolo et al., 2012).
Therefore, recognition of an absent or deficient CD4+ Th1
response may predict patients at risk for treatment failure and
poor prognosis, but also correction of an inadequate CD4+ Th1
immune response with the use of anti-HER2 dendritic cell (DC)
vaccines could consequently improve response to breast cancer
therapy and be an important step in prevention of recurrence.
EVIDENCE FOR ANTI-HER-2 IMMUNE
RESPONSE IN TUMORIGENESIS
Humoral and cellular response has been demonstrated in BC.
The humoral immune response is sensitized to a specific
antigen and drives adaptive immunity, where memory B cells
secrete targeted antibodies, and cytotoxic CD8+ T lymphocytes
and helper CD4+ T lymphocytes are recruited. In HER2
overexpressed cancers, this dual response permits recognition
and destruction of tumor cells. A large retrospective case-control
study demonstrated that patients with high levels of auto-
antibodies against HER2 have a decreased risk of developing
both ductal carcinoma in-situ (DCIS) and IBC (Tabuchi et al.,
2016). Healthy women had a significantly higher level of HER2
auto-antibodies than patients with breast cancer of any subtype.
However, this study found that some patients with IBC, but not in
DCIS, had very high levels of HER2 auto-antibodies, suggesting
that B cells in these women are reactivated by breast cancer cells
that antigen presenting T cells are able to access easily (Tabuchi
et al., 2016).
In addition to the anti-HER2 antibody responses observed,
cellular immune responses have been identified as a potential
prognostic and predictive indicator in HER2 overexpressed
breast cancers. Cellular immunity ismediated by cytotoxic CD8+
T cells and helper CD4+ T cells. CD8+ T cells have the
ability to recognize tumor associated antigens (TAA) with major
histocompatibility complex (MCH) class I, producing IFN-γ,
and inducing cell cycle inhibition, apoptosis and macrophage
tumoricidal activity (Mahmoud et al., 2011). CD4+T helper cells
complement the activity of CD8+T cells, by preventing tolerance
and promoting the survival of the effector and memory CD8+
cells (Bos and Sherman, 2010). The cytokines IL-2, TNF-α, and
IFN-γ, produced by CD4+ Th1 cells, play a crucial role in
enhancing CD8+ T cell proliferation and protease expression
(Bos and Sherman, 2010). Similarly, tumor antigen specific
CD4+ Th1 cells attracted to the tumor microenvironment will
secrete IL-2, TNF-α, and IFN-γ, creating an environment for
enhanced activity of antigen presenting cells (APC) (Cohen et al.,
2000). Patients with advanced breast cancers have been found
to have a significantly reduced development of T cells into Th1
cells, resulting in decreased production of Th1 cytokines (Verma
et al., 2013). These patients tend to have a poorer prognosis and
diminished response to neoadjuvant chemotherapy (Verma et al.,
2013).
CD4+ Th1 cell cytokines directly induce senescence, a state
of permanent tumor growth arrest and regression in vivo
(Braumüller et al., 2013), while also being able to induce tumor
cell apoptosis in vitro (Datta et al., 2015c). Th1 cytokines will
shut down angiogenesis and chemokine expression, resulting in
sustained tumor regression upon oncogene inactivation (Rakhra
et al., 2010; Tkach et al., 2012). Thus, oncogene inactivation
appears to induce senescence and apoptosis and activates the
immune system, while at the same time; the immune systemmay
also be inducing senescence and apoptosis. Based on this idea,
combined treatments of breast cancer cell lines in vitro with Th1
cytokines TNF-α and IFN-γ may cause oncogene inactivation
of HER2 and subsequent senescence and apoptosis (Braumüller
et al., 2013; Namjoshi et al., 2016). Similarly, in a murine model
of melanoma, T-cell cytokines IFN-γ and TNF-α synergized
with vemurafenib, a BRAF oncogene inhibitor, to induce cell-
cycle arrest of tumor cells in vitro (Acquavella et al., 2015),
underscoring the importance of CD4+T cell mediated immunity
against cancer cells.
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INCREASED TUMOR INFILTRATING
LYMPHOCYTES IMPROVE PROGNOSIS IN
HER2 POSITIVE BREAST CANCER
Tumor infiltrating lymphocytes (TIL) have been demonstrated to
have an important role in the natural progression and prognosis
of many solid cancers, including breast cancer. TILs have been
more frequently found in highly proliferative triple negative
breast cancer (TNBC), and, to a lesser extent, HER2 positive BC
(Perez et al., 2016). Presence of TILs in the tumor stroma suggest
a dynamic interaction between the immune system and tumor
cells, where cytotoxic T-lymphocytes (CTL) are recognizing
and lysing some tumor cells, while others may be escaping
immunosurveillance and going on to proliferate by evading
the immune system. The term “immunoediting” describes this
process. Despite the dynamics of immunoediting within the
tumor, it has been recognized that higher levels of TILs correlate
to a better prognosis (Mahmoud et al., 2011; Morita et al.,
2016; Perez et al., 2016). Specifically, high TIL levels in tumor
tissue is associated with increased pathologic complete response
(pCR) after chemotherapy as well as improved disease free and
overall survival (Wang et al., 2016). One study demonstrated
that lymphocyte predominant HER2 positive breast cancer
(consisting of at least 60% stromal TILs) has better recurrence
free survival when treated with chemotherapy alone, but not
with concurrent trastuzumab plus chemotherapy treatment or
trastuzumab treatment alone (Perez et al., 2016). In a secondary
analysis of the NeoALTTO Trial (Neoadjuvant Lapatinib and/or
Trastuzumab Treatment Optimization), the presence of TILs
at diagnosis was found to be a positive prognostic indicator
independent of which anti-HER2 agent was given with standard
chemotherapy (Salgado et al., 2015a). Furthermore, spontaneous
healing and regression of disease has been found in HER2
positive DCIS with high TIL (Morita et al., 2016).
The strongest predictor of pCR has been found to be in
the level of CD8+ T-lymphocytes (Wang et al., 2016). The
presence of CD4+ regulatory T cells (Treg) have not shown a
definitive correlation, while higher levels of other CD4+ T cells,
such as Th1 cells, are associated with better prognosis (Salgado
et al., 2015b). Although cytotoxic CD8+ T cells are a crucial
component of cell-mediated immunity, CD4+ T cells maintain
a crucial role in recruiting, activating and regulating adaptive
immunity. The role of CD4+ T cells in the prognostic value of
TIL has been demonstrated in TNBC, where the combination of
high CD4+ TIL along with high CD8+ TIL can predict positive
clinical outcomes (Matsumoto et al., 2016). Thus, increasing a BC
patient’s ability to mount an immune response with treatments
such as DC vaccination will subsequently increase in CD8+ and
CD4+ T cells in the tumor stroma, allowing for increase in pCR.
CRITICAL ROLE OF HER2 IN DCIS
DCIS is frequently seen in conjunction with invasive BC and
is a presumed precursor to some invasive tumors. Like invasive
disease, these lesions are highly heterogeneous and have variable
morphology, clinical presentation, and receptor expression
(Harada et al., 2011). Interestingly, DCIS lesions with HER2
overexpression are more likely to be associated with invasive
disease than HER2 negative lesions (Harada et al., 2011). The
overexpression of HER2 in DCIS associated with IDC suggests
lesions in evolution and may be a fleeting characteristic (Roses
et al., 2009). For example, HER2 may actually be upregulated
as an in situ tumor evolves to invasive disease, but then is
downregulated once a more advanced stage is reached (Roses
et al., 2009). HER2-positive disease is a highly proliferating BC
subtype (Dieci et al., 2016), supporting a genomic instability
theory of HER2-positive DCIS progression to invasive disease.
HER2 expression in DCIS may also lead to HER-2 negative
IBC. HER2 positive DCIS is generally seen in association with
HER2/neu negative IDC (Harada et al., 2011; Hassett et al., 2016).
Here, the immune response against immunogenic HER2 positive
cell will occur, thereby allowing cancer cells with HER-2 negative
phenotypes to emerge. This “immunoediting” likely accounts for
the discrepancy between the rate of HER2 overexpression in
DCIS compared to IBC, where is it expressed in up to 56% of
DCIS lesions and 20-30% of IBC (Witton et al., 2003; Harada
et al., 2011). Although, HER2 positive BC is noted to be an
aggressive phenotype, HER2 positive IBC may be balanced by
immune surveillance against early stage, HER2 positive disease
(Ménard et al., 2001).
LOSS OF ANTI-HER2 TH1 IMMUNITY IN
BREAST CANCER
CD4+ T helper cells exhibit a profound effect in initiating and
maintaining anti-tumor immunity: secretion of Th1 cytokines
such as IL-2 and IFN-γ promote CD8+ cytotoxic and natural
killer cell function (Kim and Cantor, 2014), as well as induction
of MHC class II molecule expression on tumor cells (Mortenson
and Fu, 2014). In this fashion, insufficient CD4+ Th1 cell
response may facilitate the natural progression of tumor cells.
An existing anti-HER2 Th1 response in healthy donors reflects
immune recognition of theHER2molecule. HER2 is prominently
expressed during ductal outgrowth and terminal end bud
development in the breast, as well as in branching breast ductal
cells during pregnancy and lactation (Eccles, 2011). This pre-
sensitization to HER2 in healthy donors likely confers protection
against tumorigenic events (Datta et al., 2015c). Suppression of
this immune response by the tumor allows evasion of immune
surveillance and successful HER2 positive tumorigenesis.
There is a progressive loss of anti-HER2 Th1 immunity in
HER2 positive BC, where healthy donors and patients with
HER2 negative BC have preserved HER2-specific Th1 response,
compared to a deficient Th1 response in patients with HER2
positive DCIS, and a nearly absent response in women with
HER2 positive IBC (Datta et al., 2015c; Figure 1). Patients
with advanced stages of IBC with lymph node positive disease
continue to have a further reduction in Th1 response (Zhu
et al., 2014). There is evidence of a loss of anti-HER-3 CD4
Th1 responses in triple negative and ER positive breast cancer
suggesting loss of anti-oncodriver Th1 responses may be a
broader defect than just that occurring in HER-2 tumorigenesis
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FIGURE 1 | Anti-HER2 CD4+ Th1 immunity remains intact in healthy donors and in HER2 negative IBC. Compared to healthy donors, patients with DCIS
have a deficient anti-HER2 CD4+ Th1 immunity and there is a nearly absent response in patients with IBC. Patients with HER2 negative BC maintain anti-HER2 Th1
response. Administration of dendritic cell vaccines sensitized to HER2 may restore anti-HER2 Th1 immunity close to the levels of healthy donors. Th1, T helper 1 cells;
IBC, invasive breast cancer; DC, dendritic cell; DCIS, ductal carcinoma in situ.
(Fracol manuscript accepted). This loss of anti-oncodriver Th1
mediated immunity may reflect various mechanisms by which
tumor cells have succeeded in evasion of the immune response,
leading to proliferation and poor response to therapy.
Poor Th1 response may be explained by T cell inhibition,
either by T-cell tolerance to tumor antigens (PD-1 and CTLA-4
pathways) or increased pro-apoptosis of CD4+ T cells (Fas
pathway). Co-inhibitory signals such as PD-1/PD-L1 and
CTLA-1may provide a contributory role to this loss of immunity.
Under normal circumstances, the PD-l/PD-L1 and CTLA-4/B7
checkpoint pathways prevent aberrantly activated T cells from
causing autoimmunity; therefore, expression of these ligands by
tumor cells allows circumvention of the immune system. PD-1
is expressed on activated T cells, B cells, dendritic cells (DC),
natural killer cells and activated monocytes, while and its ligand,
PD-L1, is expressed on many cells and tissues such as T cells,
natural killer cells and in immune privileged sites (Ge et al., 2013).
PD-1 interaction with its ligand, PD-L1, aberrantly expressed
on tumor cells, results in T cell inactivation and apoptosis and
inhibited activation of tumor antigen-specific T cells (Rosenblatt
et al., 2012) by reducing the production of IL-2, IFN-γ, and
stimulating IL-10 production (Ge et al., 2013).
Similar to the PD-1 pathway, the CTLA-4 checkpoint pathway
alsomay be utilized by tumor cells expressing the CTLA-4 surface
receptor to counteract the activity of T stimulation (Katz et al.,
2014). The CTLA-4 receptor competitively inhibits the activity
of the T cell co-stimulatory receptor, CD28, therefore impairing
tumor-reactive T cells (Pardoll, 2012). Furthermore, CTLA-
4 inhibits CD28 co-stimulation by downregulating CD80 and
CD86 receptors on dendritic cells (Datta et al., 2015a). Blocking
the PD-1/PDL-1 and CTLA4/CD28 pathways with monoclonal
antibodies (mAb) may restore antigen presenting cell function,
improve T cell function (resulting in increased IFN-γ and TNF-α
production), and promote T cell proliferation and T cell targeting
of tumors (Ge et al., 2013).
Type I CD4+ T cells are more sensitive to activation-
induced cell death via a pro-apoptotic mechanism after chronic
antigen stimulation with MHC/peptide complex (Hamad and
Schneck, 2001; Wesa et al., 2014). In the progression from DCIS
to IBC, T cells progressively encounter increasing stimulation
from the presence of the HER2 antigen on tumor cells, so as
disease progresses, CD4+ T cells are more likely to undergo
activation-induced cell death from continued stimulation and
activation with MHC/peptide complexes. This preferential
death mechanism has been demonstrated in the CD4+ T
cells of melanoma patients with advanced disease. Circulating
tumor-associated antigen specific CD4+ T cells in patients
with advanced melanoma were found to be more likely
to undergo pro-apoptotic programming (Wesa et al., 2014).
This pro-apoptotic mechanism is likely due to upregulation
of the Fas ligand (FasL) on chronically activated T cells,
which normally helps to maintain lymphocyte homeostasis
via activation-induced cell death of activated and autoreactive
cells (Saff et al., 2004). The constant tumor burden challenge
on effector T cells increases FasL expression, and subsequent
activation-induced T cell apoptosis (Hoffmann et al., 2002),
with an overall effect of weaker anti-tumor and anti-HER2 Th1
immunity.
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Tumor-induced overexpression of Fas has been demonstrated
in various types of malignancies (Ferrarini et al., 1999; Gastman
et al., 1999; Kume et al., 1999; Cheng, 2006), and may be
a mechanism of cancer-driven immune evasion, accounting
for increased apoptosis seen in tumor infiltrating lymphocytes.
Specifically, upregulation of the Fas/FasL death pathway has
been exhibited in breast cancer, where upregulation of FasL
expression was seen with an increased apoptosis level of tumor
infiltrating lymphocytes (Cheng, 2006). Patients with circulating
breast cancer cells have been shown to have a significant increase
in Fas+ CD4+ T helper cells (Gruber et al., 2013), opening
the door for immune escape and worsening disease prognosis.
Interestingly, a preclinical murine lymphoma model eliminating
Fas or FasL expression on mouse T cells caused the T cells to
have enhanced in vivo efficacy against tumor cells by increasing
T cell survival (Saff et al., 2004). Hence, targeting of the
Fas/FasL pathway may be one mechanism to increase anti-HER2
immunity in Th1 cells.
TREG CELLS INFLUENCE ANTITUMOR
IMMUNITY
A tumor-induced immunosuppressive environment may also
contribute to loss of immune recognition of HER2 positive BC
cells. In addition to overexpression of cell checkpoint pathway
peptides and pro-apoptotic peptides, an immunosuppressive
network may be created with the use of regulatory T cells
(Treg). Normally, Treg cells prevent autoimmunity, but in a
tumormicroenvironment, Tregs may be recruited, differentiated,
expanded and activated to become a tumor Treg and potentially
disrupt anti-tumor immunity (Ha, 2009). Naïve T cells may
develop into inducible Treg (iTreg) under the influence of
various cytokines, such as TGFβ or IL-10 into FoxP3+ Treg
cells. FoxP3+ Treg cells may then accumulate in the tumor
stroma, providing a barrier to immunosurveillance (Ha, 2009).
It has been observed that patients with large, locally advanced
breast cancers have increased prevalence of Treg in the peripheral
blood and tumor microenvironment (Liyanage et al., 2002;
Verma et al., 2013). A higher percentage of the FOXP3+
Tregs in the bloodstream is correlated to poor pathological
response to neoadjuvant chemotherapy (Verma et al., 2013).
BC patients who are poor clinical responders to neoadjuvant
chemotherapy with high FOXP3+ Tregs also have a significant
reduction in the production of IFN-γ and TNF-α, consequently
creating a pronounced reduction in the Th1 cell profile
(Verma et al., 2013).
Recent evidence has suggested that Treg cells are increased in
breast cancer models and depletion or inhibition of these Treg
cells may improve anti-tumor immunity (Viehl et al., 2006; Hong
et al., 2010). Depletion of Treg, either alone or in combination
with cancer vaccination, results in an increase in tumor-specific
effectors along with slowed tumor growth and improved survival
(Viehl et al., 2006). It has been demonstrated that when T cells
are stimulated in the absence of Tregs, there is improved tumor
rejection via direct lysis and/or production of IFN-γ (Casares
et al., 2003). Furthermore, tumors induced in mice develop more
slowly and with less frequency when the mice are depleted of
Tregs (Gallimore and Godkin, 2008).
The use of DC vaccination has been shown to decrease the
prevalence of Treg by depletion or inhibition and conversion to
Th1-like effector cells. In one study, CpG-ODN stimulated DC
vaccination exhibited pro-inflammatory function and resulted in
a decrease in FOXP3+ Tregs in mice (Majumder et al., 2014).
It has been demonstrated that FOXP3+ Tregs are inhibited via
signaling through Toll-like receptors (TLR), such as TLR-2, TLR-
4, TLR-8, and TLR-9 (Lee et al., 2013). This signaling strategymay
be harnessed by using TLR4-activatedmature DCs to inhibit Treg
effects as well as convert the regulatory cells into Th1 cells (Lee
et al., 2013). In the presence of immature DCs, Tregs will inhibit
effector T cell proliferation, but DCs activated and matured with
TLR4 will secrete soluble factors that will release effector cells
from suppression by Tregs (Lee et al., 2013). In addition, Tregs
deactivated by DCs may contribute to improved immunity by
conversion into IFN-γ secreting effector cells (Lee et al., 2013).
The effect of DCs on Treg function and conversion into Th1 cells
provides another dimension to their importance in the role of
antitumor immunity and restoration of Th1 cell function.
HER2 TARGETED THERAPY AND
RESISTANCE
Before the use of monoclonal antibodies in the treatment of
cancer, HER2+ breast cancer conferred a poor prognosis. With
the advent of trastuzumab, and more recently, pertuzumab,
HER2+ breast cancer has a markedly improved overall survival
in early and advanced stage disease.
Trastuzumab (Herceptin) is a humanized, recombinant
monoclonal antibody (mAb) that binds the extracellular domain
of HER2, resulting in its internalization and degradation
with subsequent downregulation of downstream PI3K pathway
signaling and mediators of cell cycle progression (Yakes et al.,
2002). Trastuzumab has antiangiogenic effects and lowers the
proapoptotic threshold for chemotherapy (Kumar and Yarmand-
Bagheri, 2001), heralding an increase in overall survival when
given in combination with chemotherapy to patients with all
stages of HER2 positive BC.
Pertuzumab (Perjeta) is another anti-HER2 mAb, similar to
trastuzumab, approved in 2014 for in clinical use. Pertuzumab
binds to a distinctly different epitope on the extracellular domain
of HER2 than trastuzumab, blocking extracellular dimerization
of HER2 and HER3 (Gajria and Chandarlapaty, 2011), resulting
in complementary mechanisms of action (Scheuer et al., 2009;
Gianni et al., 2012; Zanardi et al., 2015). In addition to direct
binding to HER2, both mAbs induce antibody dependent cell-
mediated cytotoxicity (ADCC) and adaptive immune response
to the HER2 protein (Yakes et al., 2002; Musolino et al., 2008).
Similarly, lapatinib (Tykerb), a tyrosine kinase inhibitor
(TKI), is a small molecule inhibitor against HER2 and is
used to treat HER2 positive BC. The mAbs, trastuzumab, and
pertuzumab, target HER2 present in the extracellular domain;
lapatinib targets HER2 and EGFR receptor kinases from the
intracellular domain to prevent downstream signaling from
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the HER2/neu and epidermal growth factor receptor pathways
(EGFR) (Pohlmann et al., 2009). This distinctly different
mechanism of anti-HER2 action has led to the use of lapatinib in
the trastuzumab-refractory setting (Geyer et al., 2006). Lapatinib
is able to overcome trastuzumab resistance due to truncated
HER2 receptors, showing improvement in overall survival and
pCR, but with only modest benefit (Geyer et al., 2006; Baselga
et al., 2012).
Despite improved outcomes with the use of trastuzumab,
the duration of response seems to be limited after single-
agent therapy in the metastatic setting (Vogel et al., 2002),
and a significant portion of patients who initially respond
to the therapy and patients with advanced breast cancer
develop resistance to the mAb (Gajria and Chandarlapaty,
2011). Failure of the ADCC may occur due to decreased mAb
binding, heterogeneous expression of polymorphic receptors
on immune cells, diminished tumor antigen expression on
tumor cells, and the concentration or reactivity of immune cells
in the tumor micro-environment. Adaptive immune response
changes may also contribute to trastuzumab resistance, including
dysregulation of the downstream PI3K-AKT-mTOR pathway,
accumulation of the truncated kinase active p95-HER2, and
alternative receptor kinase signaling (Gajria and Chandarlapaty,
2011). Resistant cells may present with deletions, insertions
and missense point mutations that influence the function of
receptors, adaptor proteins and second messengers, prohibiting
trastuzumab from functioning properly (Pohlmann et al., 2009).
One attempt to combat trastuzumab resistance and improve
the potency of trastuzumab therapy is the development of an
antibody-drug conjugate to deliver cytotoxic therapy to antigen-
expressing tumors (Gajria and Chandarlapaty, 2011). Emantasine
(DM1) has been conjugated to trastuzumab (TDM-1). The
mechanism of action is similar to trastuzumab alone, in that
TDM-1 activates ADCC and inhibits PI3K signaling. However,
with TDM-1, trastuzumab allows for selective binding to tumor
cells overexpressing HER2; once bound, the DM-1 enters the
cells and eradicates them by binding to tubulin (Gajria and
Chandarlapaty, 2011; Teicher and Doroshow, 2012). T-DM1 is
currently approved for treatment of HER2 positive metastatic
breast cancer and is being used in neoadjuvant clinical trials.
HER2 EXPRESSION AND ITS RELATION
TO VACCINATION RESPONSE
The ideal response to vaccination to HER2/neu for breast cancer
treatment would be long-lived immunity to the tumor associated
antigen. Therefore, dendritic cell vaccines, which induce CD4+
T-helper cells into Th1 helper subsets, are a promising approach
to implement lasting immunity. As previously mentioned, Th1
cells have high IFN-γ secretion, which is associated with
antitumor immunity and enhances the activity of cytotoxic
CD8+ lymphocytes (Cintolo et al., 2012). CD4+ Th1 immune
response also produces other cytokines such as TNF-α, a
mediator of inflammation, and IL-2, which elicits expansion
of lymphocyte populations (Cintolo et al., 2012). In an in
vitro murine breast cancer cell line, it has been demonstrated
that the combination of the Th1 cytokines IFN-γ and TNF-α
inhibit cell growth, increase apoptosis, and downregulate HER-2
surface receptor expression (Namjoshi et al., 2016). Restoring or
enhancing anti-HER2 Th1 immunity with DC vaccination has
been shown to last for up to 60 months post-vaccination (Datta
et al., 2015c), underscoring the importance of the CD4+ Th1
helper cell response in eliciting long term antitumor immunity
via Th1 cytokine production and CD8+ CTL recruitment.
The most studied vaccines for HER2 positive breast cancer
have been peptide vaccines, more specifically, vaccination against
the E75 peptide of HER2/neu. E75 (HER2/neu 369-377) is
an immunogenic peptide from the HER2/neu protein that
is overexpressed in many breast cancers (Mittendorf et al.,
2008). Although, this peptide vaccine has shown some success
in stimulating HER2-specific immunity, with lower early
recurrence rate than placebo, late recurrences occurred in the
vaccinated group due to waning immunity, necessitating vaccine
boosters (Mittendorf et al., 2012). Given that the E75 vaccine is
a peptide vaccine that elicits a CD8+ cytotoxic T-lymphocyte
(CTL) response (Figure 2), immunization with this single HLA
class I peptide results in a low-level, short lived response
(Knutson et al., 2002). This type of response may be due to lack
of activation of other components of the immune system, such as
CD4+ T-helper cells.
The E75 peptide vaccine has had the greatest immunologic
and clinical benefit in patients with tumors that have low
HER2/neu expressing tumors (1+) (Benavides et al., 2009).
The benefit seen in vaccination of patients with low HER2/neu
expressing tumors may be due to impaired CD8+ cytotoxic T
cell recognition of tumor cells that are classically considered
HER2 positive (2+/3+). Although, the E75 vaccine increased
levels of HER2 specific CD8+ T cells, levels were not strong,
and subsequent vaccination boosters were required after levels of
CD8+ T cells waned (Mittendorf et al., 2008).
The failure of peptide vaccination to induce HER2-specific
CD8+ T cell recognition may be due to overexpression
of HER2 causing reduced levels of major histocompatibility
complex (MHC) class I, and decreased number of molecules
of the antigen processing and presenting machinery (APM),
allowing tumor escape from immunosurveillance (Mimura et al.,
2011). Associated downregulation of class I expression reduces
susceptibility of tumor cells to class I-dependent CD8+mediated
lysis (Datta et al., 2015d; Figure 2). One group attempted
to ameliorate the deficiency in CD8+ T cell induction by
peptide vaccines by developing a non-replicative vector targeting
dendritic cells in amurinemodel (Tran et al., 2016). By delivering
the vaccine with a Shiga Toxin B (STxB) vector, high levels of
long-lasting multifunctional, cytotoxic, and high avidity E75-
specific CD8+ T cells were obtained. Although the response to
the vaccine in combination with a vector was more pronounced,
only tumors expressing low levels of HER2 derived the most
benefit (Tran et al., 2016).
Targeting of high HER2 expressing tumor cells (2+/3+) is
significantly dependent on the cooperation of Th1 cytokines
and the trastuzumab-mediated HER2 blockade (Datta et al.,
2015d). IFN-γ and TNF-α in combination with trastuzumab
and pertuzumab mediate the restoration of MHC class I
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FIGURE 2 | Breast cancer cells with low HER2 expression exhibit high MHC class I expression and are therefore more easily recognized by CD8+ T
cells, allowing for tumor cell killing. Peptide vaccination elicits CD8+ T cell recognition of BC cells and increases tumor cell lysis. BC cells exhibiting high HER2
expression have downregulation of MHC class I expression, inhibiting CD8+ T cell recognition. BC cells also express PD-L1 and CTLA-4, ligands in cell checkpoint
pathways that will inhibit activation of CD8+ and CD4+ T cells, respectively. Administering HER-2 pulsed type I polarized dendritic cell vaccines allows for increased
anti-HER-2 CD4+ Th1 cell activation, that secrete IFN-γ and TNF-α, which will upregulate expression of MHC class I, increasing sensitivity to CD8+ CTL mediated
lysis. The addition of trastuzumab or pertuzumab to increased IFN-γ and TNF-α expression amplifies MHC class I upregulation. IFN-however increases PD-1L on
breast cancer cells that can be blocked by addition of checkpoint inhibitors against PD-L1 and CTLA-4, further maintaining CTL recognition and lysis of tumor cells.
CTL, cytotoxic T lymphocyte, MHCI, major histocompatibility complex I; TCR, T cell receptor; DC, dendritic cell; PD-1/PD-L1, programmed cell death
protein/programmed cell death protein ligand 1; Th1, T helper cell 1; CTLA-4, cytotoxic T lymphocyte associated protein-4.
expression and promotion of HER2-CD8+ T cell targeting
against HER2 positive cancers (Datta et al., 2015d; Figure 2). By
enhancing induction of Th1 cells, and therefore Th1 cytokines,
DC vaccination against HER2 improves this response. In vitro
studies provide a possible explanation for this synergistic effect—
trastuzumab promotes receptor internalization, HER-2 protein
degradation, and MHC class I peptide presentation of the
vaccinated peptide, thereby increasing tumor lysis (Mittendorf
et al., 2006). Indications for trastuzumab are HER2/neu
overexpressing tumors with IHC 3+ or FISH ≥ 2.2, node
positive, andmetastatic breast cancer patients (Vogel et al., 2002).
Therefore, when trastuzumab is given for its specified indication,
the effect is twofold: (1) humoral immunity against HER2, and
(2) induction of Th1 cytokines to promote HER2 positive cancer
cell recognition and destruction.
IMMUNE RESPONSE IN HER2 POSITIVE
BREAST CANCER CAN PREDICT
OUTCOMES
Until recently, there has been a lack of measurable and
modifiable immune signatures available to correlate with the
success or failure of neoadjuvant chemotherapy in achieving
pCR. Achievement of pCR is one of the strongest predictors of
disease control and survival, and patients achieving pCR after
neoadjuvant chemotherapy plus anti-HER2 therapy have a more
favorable prognosis, with a decrease in recurrence and increase
in long-term survival (Untch et al., 2011; Kim et al., 2013).
Identifying genomic markers related to treatment response in
HER2/neu positive breast cancer is important in detecting
patients at risk for tumor recurrence after treatment. Identifiable
factors are immune response genes that may be expressed on
tumor cells or may be factors expressed and detected in a patient’s
peripheral blood. The monoclonal antibody trastuzumab is
standard treatment for HER2 positive breast cancer, but because
some patients have a poor response or relapse after treatment,
and recognizing relevant genes corresponding to treatment
response is of particular importance. HER2 overexpression in BC
is not predictive of either significant response to treatment or risk
of relapse. However, identification of other genes correlating to
treatment response may direct therapy.
A cohort of immune function genes expressed on tumor
cells may predict which patients with HER2 positive breast
tumors benefit from adjuvant trastuzumab treatment. Relevant
pathways and gene expression signatures on immune-related
genes have been found to be associated with treatment response
and likelihood of recurrence (Perez et al., 2015; Dieci et al.,
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2016). The pathways associated with increased recurrence free
survival after adjuvant trastuzumab include: cytokine-cytokine
receptor interaction, T-cell receptor signaling in CD8+ T cells,
interferon gamma pathway, tumor necrosis factor receptor
signaling pathway, cell surface interaction at the vascular
endothelium, and class I PI3K signaling event pathways (Perez
et al., 2015). Whole transcriptome analysis of a HER2 positive
breast cancer cohort by Perez et al. demonstrated a strong
association between immune gene expression and recurrence
free survival following treatment with adjuvant trastuzumab
(Perez et al., 2015). Tumors that are positive for these immune
function genes show a positive correlation with recurrence-free
survival after adjuvant trastuzumab therapy. The trastuzumab
risk (TRAR) prediction model is based on expression levels of
41 genes predictive of early relapse (Triulzi et al., 2015). In
particular, tumors with low risk of relapse (TRAR-low) had
enhanced expression and enrichment of immune associated
pathways and, subsequently, a higher immune cell infiltrate in
the tumor milieu. These studies support the association between
immune gene expression and recurrence free survival, suggesting
that a subset of patients with highly immunologic HER2 positive
tumors are more likely to benefit from treatment with adjuvant
trastuzumab. In the future, patients with low expression of
these genes may be identified and given other chemotherapy
combinations, in addition to HER2- sensitized dendritic cell
vaccines to restore immune response against HER2 positive
cancers.
Recently, our group has shown anti-HER2 Th1 response
to be a systemic immune correlate to pCR, and may be
a sufficient measure of immune monitoring and risk of
recurrence in patients with treated HER2 positive IBC (Datta
et al., 2015b, 2016). In patients receiving trastuzumab-based
neoadjuvant chemotherapy, anti-HER2 CD4+ T cell immunity
was dramatically higher in women obtaining pCR, compared to
those with residual disease (Datta et al., 2015b). This correlation
provides an avenue for estimating pCR after neoadjuvant HER2-
directed treatment plus chemotherapy. Patients with a lack of
pCR may be due to a depressed anti-HER2 Th1 cell response
(Datta et al., 2015b). For example, a pilot study evaluating the
anti-HER2 Th1 response in 95 HER2 positive invasive breast
cancer patients treated with standard curative therapy suggested
that a depressed anti-HER2 Th1 response correlates to increased
risk of recurrence (Datta et al., 2015b). Furthermore, it appears
as though absent tumor-level Th1 gene expression and deficient
circulating anti-HER2 Th1 immunity may predict failure of
HER2-targeted therapy (Datta et al., 2016). These results suggest
that CD4+ Th1 cells provoke an important antitumor immune
response, even when patients are given HER2 targeting agents.
Therefore, patients with residual disease after chemotherapy
or resistant lesions after HER2 targeted therapy may benefit
from restoration of this anti-HER2 response. In patients with
depressed anti-HER2 Th1 response and incomplete response to
trastuzumab plus chemotherapy, supplementation of treatment
with a HER2 targeted dendritic cell (DC) vaccination have
been found to drive an increased anti-HER2 response (Datta
et al., 2015b; Figure 1). Tracking anti-HER2 Th1 immunity
using peripheral blood draws may identify patients at increased
risk for recurrence based on fluctuations in Th1 immunity,
allowing for much earlier therapeutic intervention (Datta et al.,
2016).
RESTORATION OF ANTI-HER2 TH1
IMMUNE RESPONSE
The Th1 response has not only proven to be an immune correlate
to pCR, but may also be modified to improve patient outcomes.
Anti-HER2 Th1 response has the potential to be restored with
the use of HER2-sensitized dendritic cell (DC) vaccines. DCs are
pulsed with synthetic HER2 peptides, which, although confer a
more selective portion of the protein, have been shown to be
better processed by DCs than a whole protein. This improves
cross-presentation and activation of CD8+ T cells (Rosalia et al.,
2013).
DCs deliver co-stimulatory signals to T cells, stimulating
activation and polarization of CD8+ T cells into CTLs
and CD4+ T cells into Th1, Th2, and Th17 cells (Kaiko
et al., 2008). HER2-pulsed DC vaccination will also boost
effectiveness of anti-HER2 immunity by increasing IL-12
production, which increases T cell functionality by polarizing
T cells into the INF-γ and TNF-α secreting Th1 phenotype
in vivo, promoting anti-tumor immunity (Koski et al., 2012).
It has been demonstrated in an in vitro model of HER2-
overexpressing cells that an increase in INF-γ and TNF-α will
upregulate expression of MHC class I, therefore increasing
sensitivity to CD8+ T cell mediated lysis (Datta et al.,
2015d). The dual combination of INF-γ and TNF-α secreted
by Th1 cells has been shown to be responsible for the
clinical effects of DC vaccination by increasing tumor cell
apoptosis, senescence and HER2 receptor downregulation
(Namjoshi et al., 2016; Figure 2). The paired cytokines activate
caspase-3, which is linked to downstream apoptotic processes
starting after only 5 h of cytokine exposure (Namjoshi et al.,
2016). Addition of trastuzumab to the combination of INF-γ
and TNF-α only amplifies this result, likely due to its
inhibitory effect on both the MAPK and PI3K/AKT pathways,
allowing INF-γ/TNF-α to potentiate class I upregulation
(Datta et al., 2015d; Figure 2).
After administration of DC vaccines to HER2 positive DCIS
and stage I breast cancer patients, substantial anti-HER2 Th1
immunity is induced (Figure 1), with pCR rates approaching
25%, with loss of the target antigen in the remainder of patients
(Sharma et al., 2012; Datta et al., 2015b). When HER2-pulsed DC
vaccines were given to patients with an anti-HER2 Th1 immune
deficit in the neoadjuvant setting, anti-HER2 Th1 immunity was
restored and observed for up to 60 months post-vaccination
(Datta et al., 2015c). This restoration of Th1 immunity is not
seen with neoadjuvant trastuzumab and/or chemotherapy (Datta
et al., 2015c). Deficient anti-HER2 Th1 immunity is associated
with incomplete response to neoadjuvant therapy. Fortunately,
even in patients who have had several rounds of pretreatment,
loss of Th1 immunity can be rectified with HER2 pulsed DC
vaccination (Datta et al., 2015b). DC vaccination, therefore, has
the ability to restore and improve anti-HER2 Th1 immunity
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in the neoadjuvant setting, suggesting a role for combination
therapy with DC vaccination to enhance achievement of pCR.
OPPORTUNITIES FOR COMBINING
DENDRITIC CELL VACCINES WITH
STANDARD ANTI-HER2 THERAPY
Although, there have been revolutionary advances in drug
development for HER2-directed therapy in breast cancer, a
significant portion of treated patients do not achieve pCR,
and/or develop resistance to treatment. For example, patients
who receive trastuzumab and cytotoxic chemotherapy in the
neoadjuvant setting have a 40–60% pCR rate (Gianni et al., 2010;
Untch et al., 2011; Kim et al., 2013). Heterogeneity of HER2
overexpression is a primary cause of an incomplete response,
but immune responses related to trastuzumab resistance may
also contribute to these residual tumors (Datta et al., 2015c).
Vaccination against HER2 has been shown to significantly
boost and maintain immunity to HER2 in trastuzumab
treated patients, allowing the immune system to overcome
resistance to HER2 targeted therapy by restoring MHC class
I expression on HER2 high tumor cells (Datta et al., 2015d).
Increased MHC class I expression therefore induces enhanced
killing by HER2-stimulated cytotoxic T lymphocytes (CTL)
(Mittendorf et al., 2006; Disis et al., 2009), improving rates
of pCR.
Trastuzumab has been evaluated in combination with
anti-HER2 vaccination more than other newer agents with
similar functions, such as pertuzumab and TKIs such as
lapatinib. Although pertuzumab has not yet been studied in
combination with vaccinations, its similar mechanism of action
to trastuzumab likely will lend itself to similar results when
administered concurrently with DC vaccines. A phase I trial of
lapatinib and HER2 vaccination has been tested and another
TKI, ataxinib, has already demonstrated improved therapeutic
efficacy when combined with anti-HER2 DC vaccination
in a preclinical model of murine melanoma, opening the
door for further studies (Bose et al., 2012; Hamilton et al.,
2012).
Blockade of checkpoint pathways may also allow
improvement in efficacy of targeted immunotherapies, such
as DC vaccination. PD-1/PD-L1 signaling can inhibit DC
maturation, as well as decrease the interaction between DCs and
T cells, so abrogation of this pathway would improve subsequent
immune response (Ge et al., 2013). In a murine model of human
breast cancer, blockade of the PD-1/PD-L1 pathway using a
monoclonal antibody yielded improved therapeutic efficacy
of DC vaccination with prolonged survival and prevention of
tumor growth (Ge et al., 2013). Similarly, when DC vaccination
was combined with aOX40 (anti-CD134)/aCTLA-4 (anti–
cytotoxic T-lymphocyte–associated protein 4) monoclonal
antibody in a mouse mammary carcinoma model, overall
survival was significantly improved (Linch et al., 2016). The
combination of aOX40 and DC vaccination increased CD8+
T cell specificity and response, as well as promoted a robust
Th1 cell response as evidenced by increased levels of IFNγ,
TNFα, and IL-2 production (Linch et al., 2016). In vitro studies
have also shown that synergy between the Th1 cytokines
IFN-γ and TNF-α, which have increased production after
DC vaccination, and trastuzumab induces PD-L1 expression
and MHC class I upregulation on HER2- overexpressing
cells in vitro, facilitating CD8+ T cell recognition of tumor
cells (Datta et al., 2015d; Figure 2). Therefore, given in
combination with checkpoint inhibitors, DC vaccination
provides a synergistic promotion of Th1 response and increases
the frequency of tumor infiltrating CD4+ and CD8+ T
cells (Linch et al., 2016), ultimately providing an improved
prognosis.
FUTURE OUTLOOK
In the evolving field of cancer immunotherapy, the HER2/neu
tumor associated antigen has developed a central role.
Monoclonal antibodies against this antigen have yielded
considerable success in treating HER2 positive breast cancer, but
resistance to this therapy is a significant limitation. Identification
of a loss of anti-HER2 CD4+ Th1 response in tumorigenesis,
and its correlation to a poor response to traditional traztuzumab
plus chemotherapy, have paved a path toward the potential
for restoration of this response with anti-HER2 dendritic cell
vaccination therapy. The use of DC vaccination in combination
with traditional HER2-directed therapy has yielded promising
results due to reestablishment of Th1 immunity, resulting
in increased production of Th1 cytokines and subsequently
improved patient outcomes. Th1 cytokines maintain a crucial
role in the tumor microenvironment by enhancing MHC
class I expression, PD-L1 expression, apoptosis, and tumor
senescence therefore restoring IFN-γ through systemic
administration offers opportunity to enhance effectiveness
of standard chemotherapy and HER-2 directed therapy.
Monitoring levels of anti-HER2 Th1 responsivity may help
identify vulnerable patient populations at risk for treatment
failure provide means for early intervention by vaccination for
immune restoration. Monitoring and correcting the cellular
immune response against HER2 may prevent recurrence in
high-risk patients with DCIS and in IBC. Elucidating this
critical role for anti-HER2 Th1 immunity has shaped the
landscape of breast cancer immunotherapy, and will further
prove to be an essential component of future breast cancer
treatment.
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